The GEBT is a nonradioactive, noninvasive, orally administered test for measuring the rate of solid phase gastric emptying (GE), after consumption of a standardized 13C-enriched meal. GEBT T1/2 is the time for half of the ingested meal to leave the stomach. It is reported using kPCD, a mathematical expression of a test subject's 13CO2 excretion rate per minute at any measurement time t relative to the dose of 13C contained in the test meal.

The Intent-to-Treat (ITT) Population included all randomized subjects. During the course of the study, the GEBT kits for 11 subjects in Cohort 2 and all subjects in Cohort 3 were discovered to be unreliable and were recalled. Consequently, GEBT data for the affected subjects were not analyzed.

The GEBT is a nonradioactive, noninvasive, orally administered test for measuring the rate of solid phase gastric emptying (GE), after consumption of a standardized 13C-enriched meal. GEBT T1/2 is the time for half of the ingested meal to leave the stomach. It is reported using kPCD, a mathematical expression of a test subject's 13CO2 excretion rate per minute at any measurement time t relative to the dose of 13C contained in the test meal.

The Intent-to-Treat (ITT) Population included all randomized subjects. During the course of the study, the GEBT kits for 11 subjects in Cohort 2 and all subjects in Cohort 3 were discovered to be unreliable and were recalled. Consequently, GEBT data for the affected subjects were not analyzed.

The value and change from baseline in GEBT excretion rate (kPCD per minute) were summarized by treatment group. The value and time-matched (to baseline visit) change from baseline of the GEBT results for each post-meal time point were also summarized by treatment group.

The Intent-to-Treat (ITT) Population included all randomized subjects. During the course of the study, the GEBT kits for 11 subjects in Cohort 2 and all subjects in Cohort 3 were discovered to be unreliable and were recalled. Consequently, GEBT data for the affected subjects were not analyzed.

The percent change from baseline in GEBT excretion rate (kPCD per minute) was summarized by treatment group. The percent change from baseline of the GEBT results for each post-meal time point was also summarized by treatment group.

The Intent-to-Treat (ITT) Population included all randomized subjects. The Intent-to-Treat (ITT) Population included all randomized subjects. During the course of the study, the GEBT kits for 11 subjects in Cohort 2 and all subjects in Cohort 3 were discovered to be unreliable and were recalled. Consequently, GEBT data for the affected subjects were not analyzed.

American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary (ANMS GCSI-DD) total and subscale scores and change from baseline for the Intent to Treat Population using the protocol-specified scoring method and the manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

The Intent-to-Treat Population included all randomized subjects

American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary(ANMS GCSI-DD) total and subscale scores percent change from baseline for the Intent to Treat Population using the protocol-specified scoring method and the manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

The Intent-to-Treat Population included all randomized subjects

American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary (ANMS GCSI-DD) subscale scores and change from baseline for the Intent to Treat Population using the manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

The Intent-to-Treat Population included all randomized subjects

American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary(ANMS GCSI-DD) subscale scores percent change from baseline for the Intent to Treat Population using the protocol-specified scoring method and the manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

The Intent-to-Treat Population included all randomized subjects

American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary (ANMS GCSI-DD) subscale scores and change from baseline for the Intent to Treat Population using the protocol-specified scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

The Intent-to-Treat Population included all randomized subjects.

American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary(ANMS GCSI-DD) subscale scores percent change from baseline for the Intent to Treat Population using the protocol-specified scoring method and the manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

The Intent-to-Treat Population included all randomized subjects.

American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary (ANMS GCSI-DD) subscale scores and change from baseline for the Intent to Treat Population using the protocol-specified scoring method and manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

The Intent-to-Treat Population included all randomized subjects

American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary(ANMS GCSI-DD) subscale scores percent change from baseline for the Intent to Treat Population using the protocol-specified scoring method and the manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

The Intent-to-Treat Population included all randomized subjects

American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary (ANMS GCSI-DD) subscale scores and change from baseline for the Intent to Treat Population using the protocol-specified scoring method and manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

The Intent-to-Treat Population included all randomized subjects.

American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary(ANMS GCSI-DD) subscale scores percent change from baseline for the Intent to Treat Population using the protocol-specified scoring method and the manual scoring method. ANMS GCSI-DD is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in gastroparesis. The ANMS GCSI-DD assesses nausea/vomiting, postprandial fullness/early satiety, and bloating on a severity score calculated from a 5-point Likert scale. The ANMS GCSI-DD symptom score ranged from 0 to 4 with higher scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

The Intent-to-Treat Population included all randomized subjects.

CMAX is defined as the maximum observed drug concentration after administration.

PK Evaluable Population included all subjects who received CIN-102 and had sufficient plasma concentration data to characterize at least 1 PK parameter.

CMAX is defined as the maximum observed drug concentration after administration.

PK Evaluable Population included all subjects who received CIN-102 and had sufficient plasma concentration data to characterize at least 1 PK parameter.

TMAX is defined as the time to maximum plasma concentration.

PK Evaluable Population included all subjects who received CIN-102 and had sufficient plasma concentration data to characterize at least 1 PK parameter.

TMAX is defined as the time to maximum plasma concentration.

PK Evaluable Population included all subjects who received CIN-102 and had sufficient plasma concentration data to characterize at least 1 PK parameter.

AUC0-12 is defined as the area under the plasma concentration-time curve from pre-dose (Time 0) to 12 Hours on Day 1 of CIN-102 dosing.

PK Evaluable Population included all subjects who received CIN-102 and had sufficient plasma concentration data to characterize at least 1 PK parameter.

AUCtau is defined as the area under the plasma concentration-time curve over the dosing interval.

PK Evaluable Population included all subjects who received CIN-102 and had sufficient plasma concentration data to characterize at least 1 PK parameter.

Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) total score and change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

The Safety Population included all randomized subjects who received study drug.

Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) total score percent change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

The Safety Population included all randomized subjects who received study drug.

Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score and change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

The Safety Population included all randomized subjects who received study drug.

Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score percent change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

The Safety Population included all randomized subjects who received study drug.

Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score and change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

The Safety Population included all randomized subjects who received study drug.

Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score percent change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

The Safety Population included all randomized subjects who received study drug.

Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score and change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

The Safety Population included all randomized subjects who received study drug.

Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score percent change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

The Safety Population included all randomized subjects who received study drug.

Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score and change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

The Safety Population included all randomized subjects who received study drug.

Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score percent change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

The Safety Population included all randomized subjects who received study drug.

Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score and change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

The Safety Population included all randomized subjects who received study drug.

Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score percent change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

The Safety Population included all randomized subjects who received study drug.

Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score and change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

The Safety Population included all randomized subjects who received study drug.

Patient Assessment of Gastrointestinal Symptom Severity Index (PAGI-SYM) subscale score percent change for the Safety Population. PAGI-SYM is a patient-reported outcome instrument for a symptom-based clinical trial endpoint in upper gastrointestinal disorders. The PAGI-SYM assesses heartburn/regurgitation, post-prandial fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain calculated from a 6-point likert scale ranging from 0-5 with high scores reflecting greater symptom severity. The negative change from baseline indicates improvement.

The Safety Population included all randomized subjects who received study drug.

The Clinical Grading Assessment Scale is a patient and investigator reported outcome instrument for a clinical trial endpoint. Completed at Day 14, the assessment asks subjects about how their stomach/gastroparesis-related problems/symptoms compare to the period before they started treatment in the study based on a 15-point likert scale, where +7 is completely better, 0 is no change, and -7 is very much worse.

Subjects from the Intent to Treat Population (all randomized subjects) with responses available.